Biogen and ZymoGenetics took a slightly different tack, creating therapeutic proteins that soak up excess amounts of BLYS. ZymoGenetics, working with partner Serono, has just begun human trials of its drug, TACI-IG, while Biogen and partner Genentech hope to begin human testing of their compound in 2005.